
Pharmacy & health retail
Clicks JSE: CLS
- Last price
- R214.27
- Today
- +1.89%
Price and technicalsThe chart.
Clicks
Loading prices…
Clicks EdgeLong or short?
Long bias.
6 point long3 point short3 neutral
What it means
Most of the evidence supports Clicks’s price: the trend, the numbers or both point up. On these checks alone, the case leans long.
The price sits between its 50-day and 200-day averages: no clear trend.
Technical
Long-term trend
Points short
-18.3% against the 200-day average
Trading below its 200-day average: the long-term trend is down.
Why it matters. The 200-day average is the most watched line in the market. Shares above it tend to attract buyers; below it, sellers.
50-day against 200-day
Points short
50-day -21.3% against the 200-day
The 50-day average is below the 200-day: the medium-term trend is down.
Why it matters. When the shorter average crosses above the longer one, momentum is building; below, it is fading.
Against the Top 40
Points short
-4.8% in three months, Top 40 -0.9%
Lagged the Top 40 by 3.9 points over three months.
Why it matters. Shares that are beating the market tend to keep doing so for a while (momentum); laggards tend to keep lagging.
RSI (14-day)
Neutral
RSI 60
Neither stretched nor oversold.
Why it matters. The relative strength index measures how fast the price has moved. Extremes tend to cool off.
Technical gauge
Points long
5 up, 1 neutral, 3 down
Nine signals (moving averages, momentum, MACD and stochastic) read up.
Why it matters. A broad reading of the usual technical signals, so no single indicator decides.
Fundamental
Revenue growth
Points long
+7.4% on the year
Sales are growing faster than inflation.
Why it matters. Over time share prices follow sales and profits. Growth above inflation means real growth.
Earnings growth
Points long
+8.3% on the year
Profits are rising.
Why it matters. Earnings are what a share is ultimately priced on.
Valuation against peers
Neutral
13.5x forward earnings, Pharmacy & health retail 13.8x
Priced in line with Pharmacy & health retail.
Why it matters. A lower price for each rand of expected profit leaves more room for the price to rise, and less to fall.
Dividend yield
Points long
4.3%, Pharmacy & health retail 1.3%
Pays more than its peers for each rand invested.
Why it matters. A higher yield is income while you wait, and often a sign the price is low against the business.
Balance sheet
Neutral
Debt 72% of equity, store leases included
Moderate debt.
Why it matters. Heavy debt makes profits swing harder when rates or sales move, both ways. Retailers carry store leases as debt, so we only flag it at twice equity.
Analyst targets
Points long
Average target +45.2% from here (7 analysts)
Analysts on average see room to rise.
Why it matters. Sell-side analysts model the business in detail. Their targets are opinions, but they move money.
Backdrop
The economy
Points long
Retail sales
Helping: retail sales picking up.
Why it matters. What we think moves Pharmacy & health retail, read against the latest official numbers.
Each check points long (supports the price), short (weighs on it) or neutral; the lean is the count. Prices and company numbers via Yahoo Finance, the economy from official releases. A reading of the evidence, not a forecast. Artive Capital doesn’t raise outside capital; it only trades and invests Artive’s own, and has no clients. This is a screen we use to decide where to look, not a recommendation to buy or sell anything.
Company overviewIn plain words.
- 01What it sells
- Health and beauty through Clicks stores and pharmacies, plus pharmaceutical wholesale.
- 02How it makes money
- Front-shop beauty spend and dispensary traffic, backed by a big loyalty programme.
- 03What moves the share
- Store growth, pharmacy and beauty sales, and margins.
- Industry
- Pharmaceutical Retailers
- Head office
- Cape Town
- Financial year ends
- August
- Next results
- 22 Oct 2026
- Last ex-dividend date
- 01 Jul 2026
- Website
- clicksgroup.co.za ↗
Who runs it
- Bertina D. EngelbrechtCEO & Executive Director
- Gordon D. TraillCFO, Chief Support Services Officer & Director
- Bridget Ngwakwana MakhuraChief people officer
- Rachel WrigglesworthChief Commercial Officer
- Nina HindHead of Retail Finance
- Annalize BarnardCompany Secretary
As listed by Yahoo Finance, which can lag changes the company has announced. The company’s own website has the current line-up.
Beyond South Africa
58 stores outside South Africa: Namibia (26), Botswana (24), Eswatini (6) and Lesotho (2).
Namibia · Botswana · Eswatini · Lesotho
Source: Clicks Group integrated annual report 2025. The rest of Africa ↗
The companyWhat it owns, and who owns it.
Brands and businesses
- Clicks
- Clicks Direct Medicines
- UPD
The main ones, from the company’s website and annual report. Check the latest annual report: groups buy and sell businesses.
Ownership
- Insiders
- 3.5%
- Directors, founders and some strategic holders, as Yahoo classes them
- Institutions
- 76.8%
- 306 institutions hold shares
- Other holders and the public
- 19.7%
Ownership breakdown from Yahoo Finance.
FinancialsThe numbers, at a glance.
- Market value
- R49.4bn
- Price to earnings
- 15.1xForward 13.5x
- Dividend yield
- 4.3%
- Revenue
- R49.5bnlast 12 months
- Revenue growth
- +7.4%
- Earnings growth
- +8.3%
- Operating margin
- 9.1%
- Net margin
- 6.7%
- Return on equity
- 53.3%
- Debt to equity
- 72%
- Cash
- R1.2bnDebt R4.4bn
- Free cash flow
- R3.8bn
- R39.6bn2022
- R41.6bn2023
- R45.4bn2024
- R47.8bn2025
- R2.5bn2022
- R2.5bn2023
- R2.8bn2024
- R3.2bn2025
Headline numbers from Yahoo Finance, in rand, from the latest reported results. Growth compares with the same period a year earlier. Treat them as a sneak peek: read the company’s own results on SENS before relying on any of them.
What analysts sayThe sell-side view.
Consensus
Buy
7 analysts · average 2.4 on a 1 (strong buy) to 5 (strong sell) scale
43- Strong buy 0
- Buy 4
- Hold 3
- Sell 0
- Strong sell 0
Average 12-month target
R311.14
+45.2% vs today’s price
Target range
Low R235.00High R386.00
How the view has moved
- 3 months ago
- 2 months ago
- 1 month ago
- Now
Third-party ratings and price targets from sell-side analysts, as aggregated by Yahoo Finance. Yahoo does not name the analysts or firms behind JSE ratings, so we can’t either. This is what others say, not our view, and not advice.
In the newsMarkets, and everything else.
Markets Results, deals, share moves and leadership.
In the news Everything else that can move a share: shoppers, stores, workers, courts and supply.
Nothing else in the news in the last 30 days.
Headlines from Moneyweb, BusinessTech, TechCentral, Daily Maverick, Bizcommunity, News24, IOL, The Citizen, SABC News, The South African, Food For Mzansi and Marketaux. Matched to companies and sorted into topics automatically, so the odd one may be off. Not advice.
Also inPharmacy & health retail
All the shares we follow →Artive Capital doesn’t raise outside capital; it only trades and invests Artive’s own, and has no clients. Nothing on this page is advice or a recommendation to buy or sell.
The Monday briefCommerce, in your inbox.
Every Monday: last week’s moves in JSE commerce, your own shares, and the results and numbers due this week. Free, and you can unsubscribe any time.
We only use your email to send the brief. Privacy policy.
We don’t take outside money, but we always like talking markets and commerce.
For media, research and partnership questions, send us an email.
